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Central Neurotransmitter Function and
Its Behavioral Correlates in Man
by Israel Hanin*
The past decade has witnessed a tremendous increase in knowledge towards understanding the function
ofvarious brain neurotransmitter substances in behavior. Experimental observations in animals, utilizing
specific pharmacological agents, have enabled the development of certain hypotheses regarding
neurochemical substrates ofbehavior. These have led tocautious applications ofcomplementary studies in
humans. Asa result, several neurotransmitter-related hypotheseshave beendeveloped for theexplanation
of normal behavior, as well as of various abnormal behavior states in psychiatry and neurology. These
hypotheses are currently undergoing extensive investigation.
Highlights of the above sequence ofevents are presented, in order to provide as general, yet extensive,
an overview of the subject as possible. Examples are provided from both basic laboratory investigations
and from clinical findings. Principles of brain neurotransmitter function and interactions are reviewed.
Various neurotransmitter-related hypotheses of psychiatric and neurologic interest are introduced. Fi-
nally, the role that toxicants may have on behavior via alteration of brain neurotransmitter function is
discussed, using the lead intoxicated animal as an illustrative example.
Introduction
An assessment of behavior, particularly that
which is associated with changes in mood states, is,
in itself, a difficult task. The problem becomes infi-
nitely more complex when one couples that with
attempts to understand and explain behavioral
phenomena in humans by extrapolation from obser-
vations in animals. Any analysis of neurochemical
phenomena and their correlation with behavioral
function in humans, on the other hand, could be
conducted more readily in human subjects, using
available information obtained from experimental
animals. Whereas animal behavior could be radi-
cally different from one species to another,
neurochemical phenomena are generally reproduci-
ble across species in the mammalian system.
Moreover, there exists a wide reservoir of
neurochemical observations, obtained across a va-
riety of mammalian species, which could serve as
an important resource forextrapolation to man. For
this reason, scientists have been encouraged during
the past decade in their attempts to explain clinical
observations on the basis of known neuro-
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transmitter-related studies conducted on experi-
mental animals. Infact, such correlations have been
extended even further to include neurotransmitter-
related hypotheses for the etiology of a variety of
psychiatric states, including depression, mania and
schizophrenia. Ingenious biochemical approaches
have even been devised to study the validity of
these hypotheses directly in man.
The goal of this paper is to review, in general
terms, the neurotransmitter mechanisms operating
in brain and to illustrate how central neuro-
transmitter function may be critical to the control
and determination of behavior. The role of en-
vironmental toxicants in affecting behavior will also
be analyzed in the context of this information. Be-
cause ofthe general nature ofthis article, references
provided will be primarily review articles, in order
to equip the reader with a broader literature base
from which to obtain a more comprehensive cover-
age of the information at hand.
Neurotransmitters: An Overview
It is now generally believed that a number of en-
dogenous compounds function as neurotransmitters
in the central nervous system. These include the
October 1978 135substances, norepinephrine (NE), dopamine (DA),
5-hydroxytryptamine (serotonin, 5HT), acetyl-
choline (ACh), y-aminobutyric acid (GABA),
phenylethylamine, histamine, glycine, glutamic
acid, aspartic acid, taurine, and a number of pep-
tides such as substance P, and the enkephalins (1).
Neurotransmitters are stored in nerve terminals
and are believed to be released from these terminals
following stimulation ofthe nerve. A very complex
machinery is known to exist which is responsible
for the synthesis of these transmitter agents, their
storage within the nerve terminals, and their release
upon demand of the organism. This machinery in-
volves a variety of steps, including energy-
dependent transport mechanisms and sophisticated
enzyme reactions (2, 3). These steps have been ex-
tensively investigated, and are now well understood
in reference to the neurotransmitter substances,
ACh, NE, DA, and 5HT. Active research is pre-
sently underway toward establishing factors in-
volved in the synthesis, storage, degradation and
release of the other neurotransmitter candidates as
well.
Certain criteria have been established which,
when fulfilled, would qualify a compound for con-
sideration as a bona fide central neurotransmitter
agent. Specifically, the substance should be shown
to exist as an endogenous compound. Enzymes for
its synthesis and degradation and mechanisms for
its inactivation should be demonstrated within the
organism. Last, but not least, pharmacologic agents
known to alter the activity resulting from stimula-
tion of nerve terminals containing the suspected
neurotransmitter substance should induce the same
effect in response to administration ofthe suspected
compound from an external source. It is interesting
to note that, to date, only ACh has fulfllled all the
established criteria for a central neurotransmitter
agent. The weight of evidence favoring a central
neurotransmitter role for NE, DA, and 5HT is,
however, also considerable. Some of the other
mentioned compounds are known as "putative"
neurotransmitters, since available data provide for
these agents evidence ofonly a partial fulfillment of
the named criteria. Further supportive datafavoring
the role of these compounds as central neuro-
transmitter agents are forthcoming. Investigative
efforts in this area of research are presently prog-
ressing with vigor (1).
The distribution in brain of the various neuro-
transmitter agents is predicated by the neuronal
networks existing in the brain. Different nerve
tracts connect various anatomical locations in the
brain. Many are known; some have yet to be dis-
covered. In general, nerves containing a specific
neurotransmitter substance will cluster in tracts.
The area in which the tract terminates would be rich
in nerve terminals containing the specific neuro-
transmitter substance, and consequently the mea-
sured concentration of the neurotransmitter would
be high. More than one nerve tract will innervate a
particular brain area. Consequently, more than one
neurotransmitter substance could be identified and
measured in this area. For example, DA containing
neurons have been shown to project from the sub-
stantia nigra to the caudate nucleus in brain (4-6).
As would be predicted from this observation, the
caudate nucleus contains high concentrations ofthe
neurotransmitter, DA. The caudate nucleus, how-
ever, is also rich in ACh (7). It is, therefore, evident
that cholinergic (i.e., containing ACh) nerve end-
ings are concentrated in the caudate nucleus, as
well as DA-ergic nerve endings. In fact, it has been
demonstrated that a majorportion (although not all)
ofcholinergic neurons both originate and terminate
in the caudate nucleus; i.e., they exist primarily as
interneurons (8). The task of identification,
anatomic localization and quantitation of the vari-
ous neurotransmitter substances has been the sub-
ject of extensive investigation over the past two
decades and has resulted in a number of excellent
reference sources of information (4,.5, 8-13).
The very fact that more than one category of
neurons does terminate in a specific brain area has
an important telic reason. Intricate interactions
exist between the various neuronal terminals to be
found in brain areas. Nerve terminals originating
from one projection or tract are postulated to im-
pinge on nerve terminals and/or on dendrites from
cell bodies ofnerves from one or several other pro-
jections or tracts. This results in an interaction be-
tween the neurons involved. Considerthe following
simple hypothetical example of one neuronal tract
impinging on another tract. Electrical stimulation of
the first nerve tract would result in mobilization and
release of the neurotransmitter from the nerve ter-
minals of that tract. The released transmitter sub-
stance would then diffuse across the synaptic clefts
existingbetween the originating nerve terminals and
the so-called "effector" nerve terminals and/or
dendrites of the second tract which is to be influ-
enced by the released transmitter. The sum total of
this sequence would be the transmission of infor-
mation from one nerve tract to another as a com-
bined result of electrical and neurochemical
phenomena. The neurotransmitter would then
interact with receptors on the postsynaptic site and
trigger a response which would result either in the
activation or inhibition of transmission of an im-
pulse on the effector side. Whether activation or
inhibition occurs would depend upon a complex se-
quence of events related to the chemical nature of
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cal properties of the effector neuron.
A similar interaction actually occurs between
DA-containing nerve terminals within the caudate
nucleus, and the cholinergic interneurons within the
same brain area. The DA-containing nerve termi-
nals appear to impinge on dendrites of the cell
bodies of the cholinergic interneurons (14).
Moreover, DA appears to exert a tonic inhibitory
effect on the postsynaptic receptor site (15-18).
Consequently, stimulation of the release of DA
from these nerve terminals would result in the re-
duction ofactivity ofthe ACh-containing neurons in
the caudate nucleus. Alternatively, if one di-
minishes the afferent influence of the DA-
containing neurons in the caudate nucleus (e.g., by
blocking the postsynaptic DA-specific receptors
with a pharmacologic "neuroleptic" agent), one
would release the tonic inhibitory influence ofthese
neurons on the cholinergic interneurons. The end
result of this action would be a reduction in DA
activity and a concomitant increase in ACh activity
within the caudate nucleus. The cholinergic inter-
neurons, in turn, are known to impinge on other
neurotransmitter systems which extend out of the
caudate nucleus to other brain areas (19, 20).
Thus, there exists a sequence of interacting
mechanisms in the brain, each subject to the
specific characteristics of the neurotransmitter
mechanism involved. Moreover, a disturbance of
this sequence of systems would trigger a chain
reaction and attempts by the brain to restore mat-
ters back to normal. The complexity ofthis picture
is compounded when one considers the number of
intertransmitter interactions which could and do
exist in vivo; also, the number of brain areas which
are involved in these interactions. Different brain
areas control different functions in our bodies. Con-
sequently, an imbalance, whether endogenously or
drug-induced, even in a very specific brain area,
may result in a series of physiological as well as
neurological and/or mental aberrations. The nature
and extent of such aberrations would depend upon
the neuronal circuitry which hooks up the particular
affected brain area with other parts of the brain.
Neurotransmitter Interactions
and Their Clinical Correlates
In spite ofthis existing complexity, in most situa-
tions a deviation from normal physiologic function
has been attributed primarily (if not entirely) to an
imbalance in one particular neurochemical system,
or sometimes between two neuronal networks in the
brain. For example, the caudate nucleus is very im-
portant in vivo for the control of movement. As has
already been pointed out earlier, a seesaw-type in-
teraction exists under natural conditions between
DA and ACh in the caudate nucleus. An imbalance
in this interaction appears to be the cause of a
number of neurologic disorders. Specifically, Par-
kinson's disease results from a deficiency of the
DA-containing neurons, and a consequent hyperac-
tivity of the cholinergic interneurons. On the other
hand, Huntington1s chorea and tardive dyskinesias
appear to result from an exacerbation of DA influ-
ence, and a parallel reduction in cholinergic activity
in the caudate nucleus. This is evident from indirect
studies demonstrating that pharmacologic manipu-
lations through selective blockade and/or activation
of the appropriate neuronal activity result in an al-
leviation of the clinical syndrome (20).
One must, of course, always keep in mind that
other neurotransmitter systems will also be in-
volved in the etiology of the above syndromes, for
the reasons already elaborated earlier on. Current
neurotransmitter hypotheses such as those de-
scribed in the clinical situations mentioned above
are gross simplifications. They are, nevertheless,
necessary for the purpose ofinitiating some type of
systematic approach to the treatment ofthese clini-
cal syndromes.
Similar logic and reasoning as that applied earlier
to the analysis of neurochemical correlates of
neurologic disorders is also applicable in the evalu-
ation ofhypotheses ofneurotransmitter-related cor-
relates of mood and behavior in humans. By ex-
trapolation from animal research, various inves-
tigators have attempted to understand human be-
havior in terms of neurotransmitter function, or
often, dysfunction. An understanding of the mode
of action of specific, effective psychotropic agents
at the level of the nerve terminal has been instru-
mental in interpreting the mode of action of the
same drugs in human brain. Thus, for example, am-
phetamine, at early stages of ingestion, has been
shown, at the neuronal level, to stimulate the re-
lease of catecholamines (i.e., NE and DA) from
their nerve terminals (21, 22) and to increase availa-
bility of DA and NE, as well as 5HT, at their corre-
sponding postsynaptic receptor sites (21, 23-26).
Reserpine, on the other hand, results in depletion of
NE, DA and 5HT stores from their corresponding
nerve terminals (27). In humans and experimental
animals, amphetamine causes euphoria, excitation,
and hyperactivity, while reserpine generally in-
duces a state of depression and lethargy.
These findings, in combination with observations
indicating that other pharmacological agents known
to increase NE and/or 5HT activity at the post-
synaptic receptor site [e.g., the tricyclic antide-
pressants (23, 26, 28-31) and the monoamine
October 1978 137oxidase inhibitors (32)] are antidepressant agents
which will also induce behavioral excitation in ex-
perimental animals, have led to the development of
the so-called "catecholamine hypothesis of affec-
tive disorders." Expressed in simple terms, this
hypothesis states that improvement in mood is re-
lated to increased stimulation of NE receptors in
areas in brain which control mood and emotion; al-
ternatively, a reduction in stimulation of the same
NE receptors would result in dysphoria (33-35).
This hypothesis, originally expressed in 1965, has
had its share ofdetractors as well as supporters. Its
major contribution, nevertheless, is in the fact that
it has opened up a new dialogue. This hypothesis
has served to encourage other investigators to ex-
plain other clinical observations on the basis of
known neurotransmitter-related studies conducted
on experimental animals, following administration
ofpharmacological agents with known effect on the
activity of the various endogenous neurotransmit-
ters. No matter how simplistic these hypotheses
might turn out to be, and whether or not they are
eventually borne out to be true, such hypotheses
invariably will stimulate more research in the area.
The outcome of such research could only lead to a
better understanding of the various clinical entities
involved, and to the development of improved
drugs and/or methods of treatment of these syn-
dromes.
At the present time, a number of neuro-
transmitter-related hypotheses of human psychiat-
ric syndromes have been proposed, each involving
one or more specific neurotransmitter substance.
These are summarized in Table 1. Note that all
these hypotheses are fairly recent. The pros and
cons of these various hypotheses are discussed in
Table 1. Current list of proposed neurotransmitter-related
hypotheses in psychiatry.
Primary transmitter(s) Psychiatric syndrome(s)
involved implicated References
DA Schizophrenia (36, 37)
Methylated derivatives
of tryptamine, 5HT
(transmethylation Ho) Schizophrenia (38)
GABA Schizophrenia (39)
Phenylethylamine Schizophrenia (40, 41)
ACh / DA Schizophrenia/
(balance Ho) depression (42, 43)




greater detail in the corresponding references as
well as in the excellent book by Barchas et al. (46).
Approaches Used in Assessing
Central Neurotransmitter
Function in Man in vivo
One ofthe major difficulties in testing these vari-
ous hypotheses is inherent in the limitations im-
posed on any type of research which can ethically
be conducted in humans. Nevertheless, several ap-
proaches have been utilized successfully while
monitoring readily accessible tissues from living
human subjects, namely urine, blood and cerebro-
spinal fluid (CSF). Since it is impossible to sample
brain tissue in living humans, the next alternative is
to monitor precursors, metabolites, and enzymes
responsible for synthesis and degradation of the
various neurotransmitter substances, in any or all of
the above mentioned available fluids. Information
obtained from such analyses, albeit deductive, may
nevertheless provide an index of concomitant
neurotransmitter function in brain. This type of
logic has been applied to the investigation of a
number of the neurotransmitter-related hypotheses
listed in Table 1.
A representative list, which is by no means com-
prehensive, includes analyses in human subjects of
the endogenous metabolite of NE, 3-methoxy-4-
hydroxyphenylglycol (MHPG) in CSF, urine, and
plasma (44, 47); of homovanillic acid (HVA) and
5-hydroxyindoleacetic acid (5HIAA), the metabo-
lites of DA and of 5HT, respectively, in CSF (44,
45); ofACh and ofcholine, the endogenous precur-
sor of ACh, in blood, plasma, and RBC (48-50); of
the NE and DA-related enzymes, dopamine-,8-
hydroxylase, catechol-O-methyltransferase, and
monoamine oxidase in serum, RBC, and platelets,
respectively (44), and others. Attempts have been
conducted to determine whether a specific variety
of mental illness may be indicated by a deviation
from normal values in one or more of the parame-
ters tested. These findings are then interpreted as
being either supportive or contradictory to the
tested neurotransmitter-related hypothesis.
Understandably, all the existing hypotheses to
date are still undergoing the growing pangs of crit-
icism and skepticism; consequently they are re-
sulting in more efforts at documentation and con-
solidation of data. Nevertheless, these various
hypotheses have served a heuristic value in
stimulating a tremendous wave of both preclinical,
as well as clinical research within the past decade.
The productsofthis laborare yetforthcoming.
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Influence Central
Neurotransmitter Function?
The subject matter of this paper is of major im-
portance to investigators interested in behavioral
consequences of neurotoxicity. Consider, for
example the neurochemical effects of lead toxicity
in rodents. Chronic lead exposure has generally
been shown to increase central nervous system
metabolism of the neurotransmitters DA and NE;
on the other hand, central activity and metabolism
of ACh appear to be diminished following chronic
lead exposure (51). Thus, more than one neuro-
transmitter is affected in parallel as aresult ofexpo-
sure ofthe individual to the toxicant. Moreover, the
effect is not necessarily similar in the case of each
neurotransmitter substance. It has furthermore
been suggested by several investigators that the
lead intoxicated rodent may be used as a reliable
animal model for minimal brain dysfunction (MBD),
a syndrome also commonly known as hyperactivity
in humans. This suggestion is based primarily on
existing information regarding a variety of factors.
Specifically, these include the measured neurologi-
cal sequelae of lead toxicity in mice and rats; the
similarity in a paradoxical response of both MBD
patients and lead-treated animals to the phar-
macological agents amphetamine and phenobarbi-
tal; and the clinical observation ofa possible corre-
lation in young children between the incidence of
MBD, and ofsubclinical toxicity in these same chil-
dren as a result ofexposure to high concentrations
oflead (51, 52).
Other environmental toxicants have also been
shown to induce neurologic symptoms similar to
those seen during neurotransmitter imbalances in
humans. For example, chronic manganese poison-
ing has been implicated on the development of a
Parkinsonian syndrome in humans and monkeys
(53). Moreover, cobalt has been shown to induce
epilepsy following its cortical implantation in ex-
perimental animals (54). Both toxicants have been
shown to alter neurotransmitter mechanisms in
brain while inducing their degenerative effects (53,
54). Excellent reviews on the neurologic effect of
mercury (55) and of a variety of other metals (56)
have also been published recently.
Based on this information, it is plausible that the
effects of other environmental toxicants may also
be significantly tied in with alterations in central
neurotransmitter function. It therefore may not be
too speculative to propose, on the basis ofthe con-
cepts discussed in this paper, that certain clinically
observed conditions of mood alteration, and even
certain degenerative organic syndromes, may be the
result of insidious, but definite effects of environ-
mental toxicants on humans.
Summary
By design, the information in this article has been
presented as a very general overview. Each new
aspect, discussed here in such simple terms, has
been the result of complex and lengthy investiga-
tions. Some of the points reported here are still a
subject of controversy and intensive research.
Thus, it is hoped that by no means will the reader of
this article develop the impression that the question
of central neurotransmitter function and its be-
havioral correlates in mammals, and particularly in
man, is a straightforward and clearcut issue.
On the other hand, it is just as important to em-
phasize that this area ofinvestigation has witnessed
tremendous strides within the past decade, in terms
of elucidating some of the issues described in this
paper. This is attributable primarily to two key fac-
tors. With the recent development of sophisticated
methodological approaches one can now conve-
niently measure quantitatively, and with high
specificity, very low concentrations of neuro-
transmitters, their metabolites, and their related en-
zymes. This feature, plus an ever-growing dialogue
between basic and clinical researcher, are paving
the way for the development of an increasing
number of clinically oriented research projects,
with the eventual goal ofunderstanding more about
endogenous factors contributing to behavioral aber-
rations, and consequently, to their successful
treatment in humans.
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